1200 mg/day for 85-105 kg

2 trials

Sponsors

Virchow Biotech, Virchow Biotech Pvt Ltd

Conditions

Health Condition 1: B182- Chronic viral hepatitis C

Phase 4

Efficacy and safety of PEG-Inferon (peginterferon alpha-2b) for the treatment of chronic hepatitis C - An open-label study in India.

Active, not recruitingCTRI/2011/091/000028

Virchow BiotechHealth Condition 1: B182- Chronic viral hepatitis C

Target: 100Updated: 2021-11-24

Efficacy and safety of PEG-Inferon (peginterferon alpha-2b) for the treatment of chronic hepatitis C - An open-label study in India.

Active, not recruitingCTRI/2015/02/005494

Virchow Biotech Pvt LtdHealth Condition 1: B182- Chronic viral hepatitis C

Target: 100Updated: 2021-11-24